Additionally, the therapeutic efficacy of ADV-ApoA1 in GBM models was nullified after depleting CD8+ T cells, indicating that the anti-tumor effect of ADV-ApoA1 is dependent on CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.